Introduction
============

Use of mild therapeutic hypothermia, or \"targeted temperature management\" as recently suggested \[[@B1]\], has been recommended in cardiac arrest (CA) patients since the publication of two randomized clinical trials in 2002, the results of which demonstrated a significant improvement in neurologically intact survival for comatose CA patients presenting with ventricular fibrillation (VF) or ventricular tachycardia (VT) \[[@B2],[@B3]\]. Current guidelines suggest that mild therapeutic hypothermia should also be considered in patients presenting with other rhythms although this has been less well studied \[[@B4]\].

Although therapeutic hypothermia has been widely implemented \[[@B5]\], its benefits are still questioned and several issues remain unanswered, including the optimal time to initiate cooling. Animal data have indicated that early cooling after return of spontaneous circulation (ROSC) produces better brain function and neurological recovery than does normothermia, whereas delaying therapeutic hypothermia significantly limited these beneficial effects \[[@B6],[@B7]\]. There are also experimental data suggesting that hypothermia initiated during cardiopulmonary resuscitation (CPR), that is, intra-arrest, is superior to cooling initiated after ROSC, both in terms of increased rates of successful CPR and improved survival \[[@B8]-[@B11]\]. Experimental investigations have also shown that intra-arrest therapeutic hypothermia (IATH) increases the success rate of defibrillation attempts in VF \[[@B12]\] and has beneficial effects on heart function, including improved left ventricular function and reduced myocardial infarct size \[[@B13]\]. Clinical investigations have shown that pre-hospital induction of therapeutic hypothermia is feasible \[[@B14]\], without major adverse events even when used intra-arrest \[[@B15]\], and may provide some additional benefits over delayed in-hospital cooling \[[@B16]\].

The objective of this systematic review of the literature was, therefore, to evaluate whether IATH affects survival and neurological and cardiac function in experimental and human CA.

Materials and methods
=====================

Search strategy
---------------

The following databases were searched up to 30 July 2011: PubMed (from 1966), EMBASE (from 1974), CINAHL (from 1982), the Cochrane Library (from 1974) and Ovid/Medline (from 1966). The search strategy used the following terms: \"arrest\" OR \"cardiac arrest\" OR \"heart arrest\" AND \"hypothermia\" OR \"therapeutic hypothermia\" OR \"cooling\". References from identified studies and relevant review articles were also searched for additional eligible citations. The search was limited to English publications and was conducted in accordance with the International Liaison Committee on Resuscitation (ILCOR) process of evidence evaluation \[[@B17]\].

Study selection
---------------

Two authors (KD and FST) independently reviewed citations, abstracts and full-text articles to select eligible studies. We excluded: a) review articles; b) case reports; c) experimental studies other than animal studies (for example, cell culture, isolated organs); d) studies focusing on induced circulatory arrest (for example, for aortic arch surgery). During the selection process, we included all studies in which hypothermia was initiated before ROSC (that is, during CA); we then excluded studies in which IATH was not used alone (for example, together with cardiopulmonary bypass (CPB)). In case of disagreement, the eligibility of an article was decided by consensus among all authors (step 1).

For animal studies, we restricted studies to those that included a control group (either treated with normothermia or by conventional therapeutic hypothermia, that is, post-arrest therapeutic hypothermia (PATH), or another IATH group) and reported at least one of the following outcomes: a) overall mortality; b) brain function (neurological status, cerebral perfusion and/or metabolism); b) heart function (for example, rate of ROSC, characteristics of CPR, cardiac perfusion and performance) (step 2).

Data abstraction and study quality
----------------------------------

For each eligible study, two authors (SS and FST) independently abstracted data regarding: a) study design; b) characteristics of the study population; c) sample size; d) outcome measurements; and e) study quality. No attempt was made to re-analyze the data. Studies were classified by level of evidence (LOE) for studies with therapeutic interventions (Table [1](#T1){ref-type="table"}) and quality (poor, fair or good) according to published definitions (step 3) \[[@B17]\]. Inter-observer agreement was calculated using percent agreement and the kappa statistic. The percent of agreement (kappa statistic) for each stage of selection was: step 1 = 89% (k, 0.87); step 2, 98% (k, 0.96); step 3 = 100% (k = 1).

###### 

ILCOR levels of evidence for therapeutic interventions

  ----------- ---------------------------------------------------------------------------------------------------------------------------------------
  **LOE 1**   Randomized controlled trials (RCTs) or meta-analyses of RCTs
  **LOE 2**   Studies using concurrent controls without true randomization or meta-analyses of such studies
  **LOE 3**   Studies using retrospective controls
  **LOE 4**   Studies without a control group (for example, cases series)
  **LOE 5**   Studies not directly related to the speciﬁc population (for example, different patients, animal models, mechanical models, and so on)
  ----------- ---------------------------------------------------------------------------------------------------------------------------------------

Review end-points
-----------------

The end-points of this study were to answer the following questions related to the use of IATH from the existing evidence:

1\) What are the effects on mortality, brain and heart functions?

2\) How should IATH be induced?

3\) What are the potential adverse events?

Results
=======

Search results
--------------

The search retrieved a total of 17,628 citations (Figure [1](#F1){ref-type="fig"}). After application of the selection criteria, 28 articles were eligible for data abstraction: 23 were on experimental CA (LOE 5) and 5 on human CA (number of patients = 808). Among the clinical studies, one was a randomized controlled trial (RCT, LOE 1) \[[@B16]\], one a retrospective \[[@B18]\] and one a prospective \[[@B19]\] controlled study (LOE 3), and two were prospective studies without a control group (LOE 4) \[[@B15],[@B20]\] (Table [2](#T2){ref-type="table"}). Table [3](#T3){ref-type="table"} shows RCTs on IATH that are ongoing in the clinical setting. The characteristics of the included studies are shown in Tables [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}.

![**Flow diagram of study selection process**.](cc11235-1){#F1}

###### 

Evidence on intra-arrest hypothermia for human cardiac arrest

  Quality of Evidence   Good   \*\* Castrén, ABCD                              
  --------------------- ------ ----------------------- ------- ------- ------- -------
                               **1**                   **2**   **3**   **4**   **5**
                               **Level of Evidence**                           

Outcomes: A, return of spontaneous circulation; B, survival of event; C, survival to hospital discharge; D, intact neurological survival; E, reduction in temperature. Evidence, \* supporting; \*\* neutral; \*\*\* opposing

###### 

Ongoing clinical trials on intra-arrest therapeutic hypothermia in cardiac arrest

  STATUS               NCT           STUDY
  -------------------- ------------- -----------------------------------------------------------------------------------------------------------------
  Active, recruiting   NCT01400373   PRINCESS: Prehospital Resuscitation Intra Nasal Cooling Effectiveness Survival Study
  Active, recruiting   NCT00886184   HITUPPAC-BIO: Intra-arrest therapeutic hypothermia in pre-hospital cardiac arrest
  Active, recruiting   NCT01413399   A pilot study of intra-arrest hypothermia in patients suffering non-traumatic out-of-hospital cardiac arrest
  Active, recruiting   NCT01173393   Rapid Infusion of Cold Normal Saline During CPR for Patients With Non-VF Out-of-hospital Cardiac Arrest (RINSE)

###### 

Summary of animal trials on intra-arrest hypothermia during cardiac arrest according to method of cooling

                                Outcomes               IATH (%)   NT (%)   PATH (%)   Species   N    Arrest     Rhythm   No-flow (min)   HT method                            IATH core temp (°C)   Time to ROSC (min)
  ----------------------------- ---------------------- ---------- -------- ---------- --------- ---- ---------- -------- --------------- ------------------------------------ --------------------- --------------------
  **SYSTEMIC COOLING**                                                                                                                                                                              
                                                                                                                                                                                                    
  **Abella**\[[@B8]\]           Survival (%, 3 days)   60         10\*     10\*       Mice      30   KCl        NA       8               Ice-water blanket                    30                    10 to 11
                                GNO (%, 3 days)        60         10\*     10\*                                                                                                                     
                                ROSC (%)               100        100      100                                                                                                                      
                                                                                                                                                                                                    
  **Albaghdadi**\[[@B35]\]      ROSC (%)               78         45                  Pigs      20   Asphyxia   NA       5               PFC-TLV                              36                    11 to 13
                                CoPP (mmHg)            14         14                                                                                                                                
                                                                                                                                                                                                    
  **Boddicker**\[[@B28]\]       Survival (%, 24 hrs)   87         0\*                 Pigs      32   EC         VF       8               Surrounding the body with ice        33                    12 to 18
                                GNO (%, 24 hrs)        87         0\*                                                                                                                               
                                ROSC (%)               87         0\*                                                                                                                               
                                CoPP (mmHg)            15         10                                                                                                                                
                                                                                                                                                                                                    
  **Menegazzi**\[[@B12]\]       Survival (%, 20 min)   57         36                  Pigs      28   EC         VF       8               ivfluid                              34                    13
                                ROSC (%)               86         43\*                                                                                                                              
                                CoPP (mmHg)            10         11                                                                                                                                
                                                                                                                                                                                                    
  **Nordmark**\[[@B22]\]        Survival (3-hrs)       80         100                 Pigs      20   EC         VF       8               ivfluid                              36                    15 to 20
                                ROSC (%)               90         100                                                                                                                               
                                                                                                                                                                                                    
  **Nordmark**\[[@B25]\]        Survival (%, 6 hrs)    100        100                 Pigs      16   EC         VF       8               ivfluid                              33                    17
                                LPR \> 30 (n)          29         88\*                                                                                                                              
                                SjO2 (%, 6 hr)         100        78\*                                                                                                                              
                                ROSC (%)               100        100                                                                                                                               
                                                                                                                                                                                                    
  **Riter**\[[@B10]\]           Survival (%, 1 hr)     100        100                 Pigs      24   EC         VF       11              PFC-TLV                              35                    22
                                ROSC (%)               88         12\*                                                                                                                              
                                CoPP (mmHg)            14         10                                                                                                                                
                                                                                                                                                                                                    
  **Shaffner**\[[@B34]\]        CBF (mL/100 g/min)     10         5\*                 Dogs      12   EC         VF       6               Ice                                  28                    NA
                                                                                                                                                                                                    
  **Staffey**\[[@B15]\]         ROSC (%)               82         27\*                Pigs      33   EC         VF       11              PFC-TLV                              33                    22
                                CoPP (mmHg)            10         10                                                                                                                                
                                                                                                                                                                                                    
  **Sterz**\[[@B6]\]            Survival (%, 3 days)   75         92       84         Dogs      36   EC         VF       10              Cold iv fluids                       34                    16 to 20
                                GNO (%, 3 days)        50         8\*      41                                                            External cooling                                           
                                NDS (3 days)           19         36\*     22                                                                                                                       
                                CPP (mmHg)             55         50       51                                                                                                                       
                                ROSC (%)               75         92       84                                                                                                                       
                                CoPP (mmHg)            42         48       43                                                                                                                       
                                                                                                                                                                                                    
  **Xiao**\[[@B24]\]            Survival (%, 3 days)   100        100      100        Rats      30   Asphyxia   NA       5               Ice water                            34                    7
                                GNO (%, 3 days)        100        40\*     80                                                                                                                       
                                NDS (3 days)           1          20\*     12\*                                                                                                                     
                                ROSC (%)               100        100      100                                                                                                                      
                                                                                                                                                                                                    
  **Yannopoulos**\[[@B13]\]     ROSC (%)               100        66\*     44         Pigs      45   CVO        VF       5               Intravascular catheter               33                    20
                                CoPP (mmHg)            21         21       20                                                                                                                       
                                LVEF (%)               32         23\*     21\*                                                                                                                     
                                                                                                                                                                                                    
  **Zhao**\[[@B27]\]            Survival (%, 7 days)   53         0\*                 Mice      45   KCl        NA       8               Blankets                             30                    10 to 11
                                GNO (%, 3 days)        66         0\*                                                                                                                               
                                ROSC (%)               93         80                                                                                                                                
                                dP/dt~max~(mmHg/s)     6000       3800\*                                                                                                                            
                                                                                                                                                                                                    
  **SELECTIVE BRAIN COOLING**                                                                                                                                                                       
                                                                                                                                                                                                    
  **Brader**\[[@B26]\]          Survival (24 hrs)      33         0                   Dogs      12   EC         VF       4               Ice bags around the head             36                    24
                                NDS (24 hrs)           37         62\*                                                                                                                              
                                ROSC (%)               82         82                                                                                                                                
                                                                                                                                                                                                    
  **Cho**\[[@B32]\]             Survival (hrs)         9.3        0.1\*               Pigs      16   EC         VF/PEA   14              TNEC                                 36 to 37              19 to 29
                                ROSC (%)               75         12\*                                                                                                                              
                                CoPP (mmHg)            25         14\*                                                                                                                              
                                                                                                                                                                                                    
  **Gelman**\[[@B33]\]          CPP (mmHg)             26         25                  Pigs      14   EC         VF       6               Cooling cap placed around the head   38                    NA
                                CBF (mL/100 g/min)     16         18                                                                                                                                
                                CoPP (mmHg)            16         18                                                                                                                                
                                MBF (mL/100 g/min)     43         80\*                                                                                                                              
                                                                                                                                                                                                    
  **Guan**\[[@B29]\]            Survival (%, 4-days)   100        29\*     86         Pigs      24   EC         VF       10              TNEC                                 34-35                 15 to 25
                                NDS (4-days)           0          400\*    0                                                                                                                        
                                                                                                                                                                                                    
  **Hagioka**\[[@B23]\]         Survival (%, 7-days)   100        100                 Rats      14   CVO        VF       5               NFC                                  37                    6
                                GNO (%, 7-days)        100        100                                                                                                                               
                                CPP (mmHg)             40         34                                                                                                                                
                                HDS                    33         71\*                                                                                                                              
                                                                                                                                                                                                    
  **Jeung**\[[@B21]\]           Survival (%, 3 days)   72         72                  Dogs      14   EC         VF       9               CF                                   35                    12 to 15
                                NDS (3 days)           18         42\*                                                                                                                              
                                ROSC (%)               100        100                                                                                                                               
                                                                                                                                                                                                    
  **Tsai**\[[@B30]\]            Survival (%, 4 days)   100        25\*     63         Pigs      24   EC         VF       10              TNEC                                 34                    15 to 25
                                ROSC (%)               100        88       88                                                                                                                       
                                CoPP (mmHg)            21         18       20                                                                                                                       
                                LVEF (%)               63         52\*     51\*                                                                                                                     
                                                                                                                                                                                                    
  **Tsai**\[[@B31]\]            Survival (%, 4 days)   100        29\*                Pigs      16   EC         VF       10              TNEC                                 34                    15 to 25
                                NDS (%, 4 days)        0          400\*                                                                                                                             
                                ROSC (%)               100        88                                                                                                                                
                                CoPP (mmHg)            21         18                                                                                                                                
                                LVEF (%)               63         53\*                                                                                                                              
                                                                                                                                                                                                    
  **Wang**\[[@B36]\]            ROSC (%)               87         25\*                Pigs      16   EC         VF       15              TNEC                                 34                    20 to 30
                                CoPP (mmHg)            25         16\*                                                                                                                              

CBF, cerebral blood flow; CF, carotid flush with cold saline fluids; CG, control group; CoPP, coronary perfusion pressure; CPP, cerebral perfusion pressure; CVO, coronary vascular occlusion; dP/dt, pressure/time ratio; EC, electrical current; GNO, good neurological outcome; HDS, histological deficit score; HT, hypothermia; IATH intra-arrest therapeutic hypothermia; KCl, potassium chloride; KT, catheter; LPR, lactate/pyruvate ratio; LVEF, left ventricular ejection fraction: MBF, myocardial blood flow; N, number; NA, not available; NDS, neurological deficit score; NFC, nasoparhyngeal cooling (saline); NT, normothermia; PATH, conventional (post-arrest) hypothermia; PFC-TLV, perfluorocarbon-based total liquid ventilation; ROSC, return of spontaneous circulation; SjO~2~, jugular bulb venous oxygen saturation; TNEC, trans-nasal evaporative cooling; VF, ventricular fibrillation; \*, *P*\< 0.05 vs. IATH

###### 

Summary of animal trials that used different methods to induce intra-arrest hypothermia during cardiac arrest.

                              Outcome                IATH (%)                 IATH (%)
  --------------------------- ---------------------- ------------------------ -----------
  **Riter**\[[@B10]\]                                PFC-TLV                  iv fluids
                                                                              
                              Survival (1-hr, %)     100                      100
                              ROSC (%)               88                       25
                              CoPP (mmHg)            14                       8 \*
                                                                              
  **Yannopoulos**\[[@B13]\]                          Intravascular catheter   iv fluids
                                                                              
                              ROSC (%)               100                      55 \*
                              CoPP (mmHg)            21                       15 \*
                              LVEF (%)               32                       17 \*
                                                                              
  **Yu**\[[@B42]\]                                   TNEC                     iv fluids
                                                                              
                              Survival (%, 4 days)   57                       29
                              ROSC (%)               100                      29 \*
                              CoPP (mmHg)            23                       12 \*

CoPP, coronary perfusion pressure; LVEF, left ventricular ejection fraction; PFC-TLV, perfluorocarbon-based total liquid ventilation; ROSC, return of spontaneous circulation; TNEC, trans-nasal evaporative cooling; \*, *P*\< 0.05

###### 

Summary of clinical trials on intra-arrest hypothermia (IATH) during cardiac arrest

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                             Setting   Method            Pts   CTRL       VF/VT (%)   Δt at admission   Δt vs CTRL       ROSC        Hospital admission   Survival all patients   Survival admitted pts
  -------------------------- --------- ----------------- ----- ---------- ----------- ----------------- ---------------- ----------- -------------------- ----------------------- -----------------------
  **Callaway**\[[@B19]\]     OHCA      Cranial cooling   22    Y (NT)     41          -0.02°C/min       NS               IATH 33%\   IATH 66%\            IATH 0%\                IATH 0%\
                                                                                                                         CTRL 0%     CTRL 15%             CTRL 0%                 CTRL 0%

  **Bruel**\[[@B15]\]        OHCA      Cold iv fluids    33    N          24          \- 2.1°C          NA               61%         61%                  12%                     20%

  **Kämärainen**\[[@B20]\]   OHCA      Cold iv fluids    17    N          59          -1.34°C           NA               71%         64%                  6%                      9%

  **Castrén**\[[@B16]\]      OHCA      Trans-nasal       194   Y (PATH)   30          -1.3°C (tymp)     -0.7°C (core)\   IATH 38%\   IATH 36%\            IATH 15%\               IATH 44%\
                                                                                                        - 1.3°C (tymp)   CTRL 43%    CTRL 42%             CTRL 13%                CTRL 31%

  **Garrett**\[[@B18]\]      OHCA      Cold iv fluids    542   Y (NT)     22          NA                NA               IATH 37%\   IATH 28%\            IATH 13%\               IATH 44%\
                                                                                                                         CTRL 27%    CTRL 23%             CTRL 12%                CTRL 51%
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Δt, difference in temperature; CTRL, control group; iv, intravenous; NA, not applicable/available; N, no; NS, not significant; NT, normothermia; OHCA, out-of-hospital cardiac arrest; PATH, conventional (post-arrest) hypothermia; Pts., patients; ROSC, return of spontaneous circulation; tymp, tympanic; VF, ventricular fibrillation; VT, ventricular tachycardia; Y, yes

Effects on mortality
--------------------

Sixteen animal and three human studies reported data on mortality.

### a) IATH versus normothermia

Nine animal studies reported similar mortality rates in IATH and normothermia groups \[[@B6],[@B10],[@B12],[@B21]-[@B26]\], and seven animal studies reported an improvement in survival rate in IATH-treated animals \[[@B8],[@B27]-[@B32]\].

In an early human trial, external cranial IATH was investigated in 22 patients during out-of-hospital cardiac arrest (OHCA) \[[@B19]\], including 9 who received cranial cooling and 13 who did not; no patients survived to hospital discharge. A recent retrospective study compared the outcome of 208 OHCA patients treated with intra-arrest cold intravenous fluids to historical controls (*n*= 334) \[[@B18]\]. The use of IATH was not associated with increased overall survival to hospital admission (28% vs. 23%) or to discharge (13% vs. 12%).

### b) IATH versus PATH

Two experimental studies reported improved survival with early IATH \[[@B8],[@B13]\] and four \[[@B6],[@B24],[@B29],[@B30]\] found no differences in mortality.

In the only RCT using IATH \[[@B16]\], OHCA patients were randomized, irrespective of their rhythm, to receive either trans-nasal evaporative cooling (TNEC, *n*= 96) or standard of care (*n*= 104, including PATH) during CPR. Overall survival rates were similar in the two groups (15% vs. 13%). Among patients admitted to the hospital, overall survival was increased, although not significantly, from 31 to 44% using IATH (*P*= 0.16). In the *post hoc*analysis, the sub-group of patients with time to CPR less than 10 minutes had an increased survival rate when treated by IATH (56% vs. 29%, *P*= 0.04). A non-significant 15% improvement in the survival rate was also observed in the small subgroup of VF patients.

Effects on neurological outcome
-------------------------------

Ten animal studies and one human study reported data on neurological outcomes.

### a) IATH versus normothermia

In five studies, more animals in the intra-arrest cooling group had a good neurological outcome compared to normothermic animals \[[@B6],[@B8],[@B24],[@B27],[@B28]\]. In six studies, the neurological deficit score (NDS, where a score of 0 indicates no neurological deficit) was significantly lower in IATH than in normothermic animals \[[@B6],[@B21],[@B24],[@B26],[@B29],[@B31]\]. Only two animal studies reported that IATH did not result in a better neurological outcome: In the first, all animals survived without neurological deficit at seen days after CA \[[@B23]\]; in the other, there were no differences in neurological outcome in terms of overall performance categories (OPC, 1 and 2 being good neurological outcome) or histological damage score (HDS) between IATH and normothermia groups \[[@B21]\]. Nevertheless, the percentage of injured neurons or the NDS was significantly lower in the IATH group compared with the normothermic group in these two studies \[[@B21],[@B23]\].

### b) IATH versus PATH

One experimental study \[[@B8]\] found a significant improvement in neurological status in animals treated with IATH compared to PATH, and another \[[@B24]\] showed a larger, although not statistically significant, number of animals with intact brain function in the IATH group.

In a human RCT, TNEC increased, although not significantly (*P*= 0.14), the intact neurological outcome rate from 21% to 34% when compared to a control group of patients admitted to hospital and cooled after CA \[[@B16]\]; these beneficial effects were more pronounced in patients with short time to CPR (43% vs. 17%, *P*= 0.03).

Effects on brain perfusion and metabolism
-----------------------------------------

Six animal studies reported data on brain perfusion and metabolism \[[@B6],[@B22],[@B23],[@B25],[@B33],[@B34]\]. No human study has reported data on cerebral perfusion and/or metabolism during IATH.

### a) IATH versus normothermia

Cerebral perfusion pressure (CPP) did not differ significantly between IATH and normothermia groups when selective brain cooling \[[@B23],[@B33]\] or a combination of cold intravenous solutions and external cooling \[[@B6]\] were used. Cerebral blood flow (CBF) and cerebral oxygen extraction rate were similar during CPR and after ROSC in IATH and in normothermic animals \[[@B22],[@B33]\]. Nevertheless, during CPR, hypothermic animals had higher blood flow in the caudate nucleus and the infra-tentorial regions than did normothermic animals \[[@B33]\], and cerebral oxygen uptake was significantly lower in hypothermic animals (44 vs. 69%, *P*= 0.02) at 45 minutes after reperfusion \[[@B33]\]. In a canine VF model of CA, IATH prevented the decrease in supratentorial blood flow and cerebral metabolic rate occurring during CPR at a CPP of 25 mmHg \[[@B34]\]. In another study, nasopharyngeal IATH resulted in a longer duration of high CBF at reperfusion when compared to normothermia \[[@B23]\]. Pigs treated with intra-arrest cooling had significantly higher values of venous jugular bulb saturation (SjO~2~), a surrogate for CBF, although CPP was similar during the study period \[[@B25]\]. Finally, cerebral metabolism was preserved during intra-arrest cooling as IATH prevented secondary increases in the lactate/pyruvate ratio (LPR) and glutamate levels when compared to normothermia \[[@B25]\].

### b) IATH versus PATH

Only one animal study has reported data on brain perfusion and metabolism \[[@B6]\]: CPP was similar in IATH and PATH groups.

Effects on cardiac function
---------------------------

Four animal studies have reported data on cardiac function \[[@B13],[@B27],[@B30],[@B31]\]. No human study has specifically investigated heart function after CA when IATH therapy was used.

### a) IATH versus normothermia

Left ventricular ejection fraction (LVEF) after CA was significantly increased by IATH compared to normothermia \[[@B13],[@B30],[@B31]\]. The ratio of infarction size to LV weight, a surrogate of degree of ischemic damage after coronary occlusion, was also noted to be significantly reduced by IATH when compared to normothermia \[[@B13]\]. Cardiac function evaluated by pressure-volume loops showed that early IATH resulted in improved cardiac output and contractility when compared to normothermia \[[@B27]\]. In another study, systolic and diastolic functions were both improved by cooling and the beneficial effects were more significant when hypothermia was initiated during CPR \[[@B31]\].

### b) IATH versus PATH

In one animal study, cardiac function during IATH was compared to that during PATH \[[@B30]\]. Both IATH and PATH improved post-resuscitation myocardial dysfunction, but the beneficial effects were greatest with IATH \[[@B30]\]. In a second study, Yannopoulos *et al*. showed that intra-arrest cooling significantly improved LVEF and reduced the ischemic myocardial damage compared to delayed cooling \[[@B13]\].

Effects on coronary perfusion pressure
--------------------------------------

Twelve animal studies reported data on coronary perfusion pressure (CoPP), defined as the difference between diastolic arterial pressure and central venous pressure, during CPR \[[@B6],[@B10]-[@B13],[@B28],[@B30]-[@B33],[@B35],[@B36]\]. No human study has reported data on CoPP during IATH.

### a) IATH versus normothermia

Ten studies showed that CoPP did not differ significantly between IATH and normothermia groups when different types of cooling were used \[[@B6],[@B10]-[@B13],[@B28],[@B30],[@B31],[@B33],[@B35]\]. One study reported a higher CoPP in the IATH group during the first three minutes of CPR, but not thereafter \[[@B10]\]. Two studies reported a higher CoPP before defibrillation when intra-arrest cooling was initiated using TNEC, compared to control normothermic animals \[[@B32],[@B36]\].

### b) IATH versus PATH

Three animal studies reported a similar CoPP in animals treated with IATH and those treated with PATH \[[@B6],[@B13],[@B30]\].

Effects on return of spontaneous circulation (ROSC)
---------------------------------------------------

Eighteen animal studies \[[@B6],[@B8],[@B10]-[@B13],[@B21],[@B22],[@B24]-[@B28],[@B30]-[@B32],[@B35],[@B36]\] and three human studies \[[@B16],[@B18],[@B19]\] reported data on ROSC rate.

### a) IATH versus normothermia

Ten experimental studies found no difference in ROSC rate between IATH and normothermia \[[@B6],[@B8],[@B21],[@B22],[@B24]-[@B27],[@B30],[@B31]\]. Albahgdadi *et al*. found a non-significant improvement in ROSC success with spontaneous circulation achieved in 78% of IATH and 45% of normothermic animals (*P*= 0.2) \[[@B35]\]. Seven animal studies reported an increase in ROSC rate with IATH \[[@B10]-[@B13],[@B28],[@B32],[@B36]\].

In two clinical studies, IATH was associated with an increased ROSC rate compared to normothermia \[[@B18],[@B19]\].

### b) IATH versus PATH

Four experimental studies found no difference in ROSC rate between IATH and PATH \[[@B6],[@B8],[@B24],[@B30]\]. One animal study noted that the ROSC rate was increased with IATH when compared to PATH \[[@B13]\]. In the human RCT using intra-arrest TNEC \[[@B16]\], patients receiving IATH had similar ROSC rates compared to the control group (38% vs. 43%).

Effects on defibrillation attempts and epinephrine dose
-------------------------------------------------------

Eleven animal studies reported data on the effects of IATH on duration and characteristics of CPR \[[@B6],[@B10]-[@B13],[@B21],[@B28],[@B30]-[@B32],[@B36]\]. No human studies have specifically reported data on duration and characteristics of CPR during IATH.

### a) IATH versus normothermia

In one study, there were no significant differences in the duration of CPR, the total dose of epinephrine administered during CPR or the number of counter-shocks given to reverse VF between animals that received IATH and those that remained normothermic \[[@B21]\]. Two other studies also found no difference in the number of defibrillation shocks required to achieve ROSC \[[@B10],[@B32]\]. Sterz *et al*. \[[@B6]\] showed no differences in requirements of counter-shocks and the dose of epinephrine or in the duration of CPR between IATH- and normothermia-treated animals.

Seven animal studies reported variable effects of IATH on duration and characteristics of CPR \[[@B11]-[@B13],[@B28],[@B30],[@B31],[@B36]\]. In one, a somewhat smaller number of countershocks was required to achieve ROSC in IATH when compared to normothermia (9 vs. 17, *P*= 0.07) but the total dose of epinephrine required was lower as was the duration of CPR \[[@B31]\]. Tsai *et al*. reported that fewer defibrillation shocks were required to achieve ROSC in IATH compared to normothermia \[[@B30]\]; the total dose of epinephrine required to achieve ROSC was also lower in IATH as was the duration of CPR. In two studies, IATH achieved ROSC with a lower number of shocks but had a similar success rate as the normothermic group for initial shocks \[[@B11],[@B12]\]. In a porcine model, the total amount of epinephrine used during the recovery period was three times less in the IATH than in the normothermia group \[[@B12]\]; however, the total number of defibrillation attempts did not differ between groups \[[@B11],[@B12]\]. In another porcine model, there was no significant difference in the number of shocks needed (7 vs. 6.9) or in the success rate of initial shocks between IATH and normothermic animals (50 vs. 12%), but the duration of CPR was shorter in the IATH group \[[@B36]\]. Boddicker *et al*. reported that the first defibrillation was successful in 12% of normothermic compared to 75% of moderately cooled IATH animals (*P*= 0.04) \[[@B28]\]; the total number of delivered shocks was lower in IATH than in normothermic animals as was the number of re-fibrillations. Finally, Yannopoulos *et al*. reported that IATH was associated with fewer shocks to first ROSC, fewer total shocks and doses of epinephrine, and a shorter duration of CPR compared to normothermia \[[@B13]\]. No human studies have specifically reported data on duration and characteristics of CPR during IATH.

### b) IATH versus PATH

Sterz *et al*. \[[@B10]\] showed no differences in requirements of counter-shocks and the dose of epinephrine or in the duration of CPR between IATH- and PATH-treated animals. In another study, IATH was associated with fewer shocks to first ROSC, fewer total shocks and doses of epinephrine, and a shorter duration of CPR compared to PATH \[[@B13]\].

Effects of methods of inducing IATH
-----------------------------------

In animal studies, IATH has been induced by various techniques/devices, including ice packs, intravascular catheters, cold metal plates or total lung ventilation with perfluorocarbon (PFC). Some devices selectively cool the brain without affecting core body temperature. Few studies have compared the effects of these different devices on outcomes.

### a) Effects of IATH method on outcomes

Three studies reported the effects of different types of IATH induction on mortality, brain or cardiac function after CA \[[@B10],[@B13],[@B37]\] (Table [5](#T5){ref-type="table"}). LVEF was significantly increased by IATH induced by an intravascular system compared to intra-arrest cold fluids \[[@B13]\]; IATH using cold fluids resulted in a lower CoPP, a greater need for epinephrine and a longer duration of CPR. In a study by Riter *et al*. \[[@B10]\], cold fluids and PFC-TLV rapidly achieved target temperature, but ROSC was achieved more easily with PFC-TLV. In a model of prolonged CA, TNEC initiated during CPR improved the success of resuscitation compared with IATH induced by cold fluids; however, no difference in the survival rate was found \[[@B37]\]. The total number of countershocks and amount of epinephrine administered to achieve ROSC was significantly lower with IATH-TNEC than with cold fluids; the duration of CPR was also significantly reduced and CoPP higher when TNEC was used.

### b) Effects of time of initiation of IATH

One experimental study investigated the role of early versus delayed induction of IATH \[[@B27]\]. Early IATH significantly improved survival and intact neurological outcome when compared to delayed IATH and was associated with improved cardiac output and contractility (evaluated by pressure-volume loops) \[[@B27]\].

### c) Effects of target temperature during IATH

Only one animal study addressed the issue of the effects of different temperature levels during IATH on outcomes \[[@B28]\]. This study showed that animals suffering from prolonged VF-arrest had a better survival rate (87%) when treated with moderate (33°C) rather than mild (35°C, 37%, *P*\< 0.001) or severe (30°C, 62%, *P*= 0.03) IATH, induced by external ice packs; ROSC rates were 87%, 37% and 62%, respectively. Moderate IATH had a higher successful VF termination rate (75%) with the first defibrillation attempt when compared to mild (50%) and severe (62%) IATH, although the number of refibrillation **{refibrillation}**episodes was similar among groups. Finally, the number of defibrillation attempts and the total energy delivered per animal were lower with deeper hypothermia.

Adverse events
--------------

No adverse events associated with IATH were reported in the animal studies. In a human study of 16 patients who underwent IATH \[[@B15]\], rapid intravenous administration of cold fluids resulted in one case of pulmonary edema, which resolved after the prompt interruption of fluid infusion. In the Prince study, TNEC resulted in transient nasal whitening in 13 of 93 (14%) patients and epistaxis in three patients (serious in one patient with an underlying coagulopathy) \[[@B16]\]. Peri-orbital emphysema occurred in one patient and resolved spontaneously within 24 hours.

Discussion
==========

This systematic review revealed that: a) in experimental models of CA, IATH improves survival and neurological outcome when compared to normothermia and/or PATH; b) IATH improved ROSC rates and was associated with improved cardiac function, including better left ventricular function and reduced myocardial infarct size, when compared to normothermia; c) data on the efficacy of IATH in humans remain limited; d) IATH is feasible and is associated with few adverse events.

Therapeutic hypothermia has been shown to provide protective effects on brain and heart cells through different pathways. Hypothermic mechanisms providing myocardial protection have not been completely elucidated but include improved energy production during ischemia \[[@B38]\], inhibition of apoptosis \[[@B27]\], increased calcium sensitivity of myocytes \[[@B39]\], regulation of mitochondrial oxidative phosphorylation \[[@B38]\], attenuation of reactive oxygen species generation after ischemia-reperfusion \[[@B40]\], and preserved myocardial vascular autoregulation \[[@B41]\]. All these mechanisms translate into increased myocardial contractility \[[@B39],[@B42]\], which should potentially be enhanced by IATH. Animal studies demonstrated a significant improvement in contractility when IATH was used in comparison with normothermia and PATH \[[@B13],[@B27],[@B30],[@B31]\] and IATH also had the potential to reduce the infarction size after coronary vessel occlusion and CA \[[@B13]\]. Nevertheless, conflicting results have been reported between IATH and normothermia and/or PATH in terms of ROSC rate, duration of CPR, CoPP, total dose of epinephrine administered during CPR and defibrillation success rate \[[@B6],[@B11],[@B12],[@B21],[@B31]\]. Variations in the experimental models could explain, at least in part, these differences. A very short ischemic period is unlikely to produce sufficient cardiovascular alteration to make it possible to demonstrate any superiority of IATH over other therapies. In one study, time from CPR to ROSC was as short as two to three minutes \[[@B8]\] and in another, all the animals achieved ROSC within one minute after CPR was initiated \[[@B23]\]. The complexity and severity of the animal model, the different durations of VF, and the methods used to induce IATH (for example, systemic vs. selective brain) may also confound comparison of these studies. A further concern is related to the limited numbers of experimental animals used, as sometimes this restricted the power of statistical analyses \[[@B35]\]. Unfortunately, human studies have reported only data on the ROSC rate; in the RCT, TNEC resulted in similar ROSC rates to those seen in the control group \[[@B16]\], whereas in a retrospective study, IATH using cold fluids was associated with a significantly increased rate of ROSC compared to historical controls \[[@B18]\]. Further studies are needed to investigate myocardial function during IATH after human CA.

Therapeutic hypothermia may also preserve cerebral function after CA through inhibition of release of neurotransmitters, such as glutamate and dopamine, involved in brain damage \[[@B43]\]; preservation of the blood brain barrier \[[@B44]\]; protection of cerebral energy stores \[[@B45]\] and microcirculation \[[@B46]\]; and decrease in intracranial pressure and increase in CBF \[[@B47]\]. Importantly, cerebral reperfusion occurring after ROSC can also trigger the production of free radicals and other neurotoxic mediators, which may enhance anoxic damage to the brain \[[@B48]\]. Thus, the beneficial effects of therapeutic hypothermia after CA should be even more pronounced when cooling is initiated during the no-flow state and/or CPR before reperfusion. The positive effects of IATH on neurological outcome after experimental CA have been well-demonstrated. IATH affects brain perfusion and metabolism, as demonstrated by increased supra- and infra-tentorial CBF \[[@B23],[@B33],[@B34]\] and decreased cerebral oxygen uptake \[[@B25],[@B33],[@B34]\], thus preventing anaerobic metabolism and excito-toxicity \[[@B25]\]. All the experimental studies showed better neurological function in animals treated with IATH compared to normothermia or PATH, as well as a reduction in the number of injured neurons on histological brain examination. In the human RCT, IATH increased the intact neurological outcome rate, particularly in patients with a short no-flow time \[[@B16]\].

The combination of these beneficial effects of IATH on cardiac and cerebral functions should be expected to improve overall survival. However, IATH reduced mortality rates in only 7 of the 16 animal studies in which it was compared to normothermia \[[@B8],[@B27]-[@B32]\] and 2 of the 6 studies in which it was compared to PATH \[[@B8],[@B13]\]. Nevertheless, some of the negative studies had methodological limitations reducing the possibility of demonstrating any beneficial effects of IATH over standard treatment. In two of the studies, the observation period after CA was less than three hours \[[@B10],[@B22]\], so that no effects on long-term outcome could be reported. In two studies, all animals survived after arrest because of a short no-flow and CPR period \[[@B23],[@B24]\], this situation being far different from the clinical scenario of CA in humans. Two studies showed an improvement, although not statistically significant, in survival rate when IATH was used \[[@B26],[@B35]\] and the authors acknowledged a limited sample size as the main reason for their findings.

Human data on the effects of IATH on mortality after CA are also scarce. External cranial cooling did not improve survival rates in OHCA compared to a control group without ice \[[@B19]\]; however, the reduction in tympanic temperature, a surrogate of brain temperature, was similar between groups. In a large retrospective database, intra-arrest cold intravenous fluids were not associated with increased overall survival; importantly, only 13% of the whole cohort received in-hospital therapeutic hypothermia. In the RCT using intra-arrest cooling \[[@B16]\], OHCA patients admitted to the hospital and receiving IATH had improved overall survival when compared to the control group although the difference was not statistically significant; these effects appeared to be even more beneficial in the sub-groups of patients with short no-flow time and VF.

If IATH is to be applied, it remains unclear which technique/device provides optimal cooling and protection. Speed of achieving target temperature in experimental studies was dependent on animal size and the duration of exposure to hypothermia during CA. These factors may limit the reproducibility of these data in the human setting. Moreover, although the neuroprotective effect of IATH may be related to how quickly the brain is cooled, systemic cooling is important for myocardial protection. Also, IATH using cold fluids resulted in a lower CoPP and decreased LVEF after CA \[[@B13]\]; the need for epinephrine and duration of CPR were also significantly longer than control animals, suggesting that post-ROSC myocardial dysfunction could be exacerbated by cold fluid loading. Cooling with an intravascular catheter, PFC-TLV or TNEC has been shown to improve ROSC rate, survival and intact neurological outcome when compared to cold fluid infusion \[[@B10],[@B13],[@B37]\]. Hence, although intravenous cold fluids have been shown to be effective and safe when applied after ROSC \[[@B2],[@B14]\], the safety of large amounts of fluid during CPR may be questioned.

Other potential methods for IATH induction also have limitations when applied to the human setting. Internal cooling with catheters is invasive and not applicable in the field. Intrapulmonary PFC with TLV would not be easy to apply and may potentially exacerbate lung injury because of increased intrapulmonary pressure during ventilation \[[@B10],[@B49]\]. Trans-nasal cooling devices spray a PFC fluid through a nasal catheter system into the nasal cavity and induce brain hypothermia via the cooled blood and by direct convection; body cooling occurs later. Further studies are needed to investigate the beneficial effects of this technique in the human setting as well as the occurrence of adverse events.

Conclusion
==========

The use of hypothermia has been associated with improved outcomes for survivors from CA; however, it has been suggested that the timing of the induced cooling may influence its beneficial effects. Experimental studies have shown that IATH can protect the heart against the ischemic processes occurring after CA and reduce the neuronal injury secondary to global ischemia. These beneficial effects seem to be significant when IATH is compared not only to normothermia, but also to PATH. Nevertheless, not all of these studies have reported similar conclusions, probably because of the different experimental conditions that have been used. Also, the evidence that IATH is superior to PATH in animal studies is more limited than the evidence comparing IATH to normothermia. Human data on IATH remain limited; however, several large cohort studies have suggested some beneficial effects of IATH on ROSC rates and neurological outcomes, especially if initiated within a short no-flow time. Selective brain cooling may have potential advantages in protecting the brain before reperfusion and has shown promising results in experimental and clinical studies; however, this technique may limit potentially beneficial effects of hypothermia on cardiac function and needs to be further evaluated in the human setting.

Key messages
============

\- IATH improves survival and neurological outcome when compared to normothermia and/or PATH in experimental models of CA.

\- IATH prevents the decrease in cardiac function occurring after CA and maintains better cerebral perfusion and metabolism during CPR when compared to normothermia.

\- Data on the efficacy of IATH in humans are still limited. One RCT showed better survival and neurological outcome in those patients receiving IATH with a no-flow time less than 10 minutes. Ongoing clinical trials will provide further data on the use of IATH in human CA.

\- In the clinical setting, external cranial cooling, cold intravenous fluids and TNEC have been used to induce IATH. Few adverse events have been reported with these techniques.
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